Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $24.42 Average Price Target from Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $24.4167.

A number of equities research analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Piper Sandler upped their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Morgan Stanley raised their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. dropped their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 492,400 shares of the stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the sale, the insider owned 812,058 shares in the company, valued at $17,775,949.62. This represents a 37.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total value of $1,145,039.80. Following the transaction, the insider owned 237,688 shares of the company’s stock, valued at $5,336,095.60. The trade was a 17.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,062,325 shares of company stock valued at $46,659,069. 5.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies in the 4th quarter valued at $28,000. Nykredit A S purchased a new stake in shares of Adaptive Biotechnologies during the second quarter worth $31,000. Allworth Financial LP purchased a new stake in shares of Adaptive Biotechnologies during the second quarter worth $35,000. EverSource Wealth Advisors LLC raised its position in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the last quarter. Finally, KBC Group NV acquired a new stake in Adaptive Biotechnologies in the 1st quarter valued at about $45,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $25.19 on Friday. The stock’s 50-day moving average is $22.92 and its 200 day moving average is $17.65. Adaptive Biotechnologies has a 1-year low of $12.00 and a 1-year high of $26.87. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The company has a market cap of $4.02 billion, a P/E ratio of -61.44 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. Research analysts predict that Adaptive Biotechnologies will post -0.4 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.